Adverse Events of Cannabidiol Use in Patients With Epilepsy
Sign Up to like & getrecommendations! Published in 2023 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2023.9126
Abstract: Key Points Question What are the frequency and risk of adverse events (AEs) developing in patients with epilepsy who are using cannabidiol (CBD)? Findings In this systematic review and meta-analysis, the frequency of any grade… read more here.
Keywords: use patients; patients epilepsy; grade aes; events cannabidiol ... See more keywords
DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols.
Sign Up to like & getrecommendations! Published in 2021 at "British journal of clinical pharmacology"
DOI: 10.1111/bcp.15144
Abstract: AIM Cancer patients with reduced dihydropyrimidine dehydrogenase (DPD) activity are at increased risk of severe fluoropyrimidine (FP)-related adverse events (AE). Guidelines recommend FP dosing adjusted to genotype-predicted DPD activity based on four DPYD variants (rs3918290,… read more here.
Keywords: risk; dpyd polymorphisms; polymorphisms 496a; risk severe ... See more keywords
Efficacy and Adverse Events of PD-1 Inhibitors in Patients With Advanced Urothelial Carcinoma From a Real-World Experience
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.837499
Abstract: Background: Programmed death 1 (PD-1) inhibitors—tislelizumab, toripalimab, camrelizumab, and sintilimab—are used for advanced urothelial carcinoma (UC) in China. To date, the efficacy and adverse events (AEs) of these PD-1 inhibitors have been poorly reported for… read more here.
Keywords: grade aes; efficacy; advanced urothelial; urothelial carcinoma ... See more keywords